Growth Metrics

Emergent BioSolutions (EBS) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $72.3 million.

  • Emergent BioSolutions' Accumulated Depreciation & Amortization fell 1268.12% to $72.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.3 million, marking a year-over-year decrease of 1268.12%. This contributed to the annual value of $108.8 million for FY2024, which is 1302.96% down from last year.
  • Per Emergent BioSolutions' latest filing, its Accumulated Depreciation & Amortization stood at $72.3 million for Q3 2025, which was down 1268.12% from $48.9 million recorded in Q2 2025.
  • Emergent BioSolutions' Accumulated Depreciation & Amortization's 5-year high stood at $143.3 million during Q4 2022, with a 5-year trough of $25.4 million in Q1 2025.
  • In the last 5 years, Emergent BioSolutions' Accumulated Depreciation & Amortization had a median value of $72.3 million in 2025 and averaged $74.3 million.
  • Per our database at Business Quant, Emergent BioSolutions' Accumulated Depreciation & Amortization soared by 14710.58% in 2021 and then crashed by 1936.42% in 2024.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Accumulated Depreciation & Amortization stood at $123.8 million in 2021, then increased by 15.75% to $143.3 million in 2022, then decreased by 12.7% to $125.1 million in 2023, then decreased by 13.03% to $108.8 million in 2024, then plummeted by 33.55% to $72.3 million in 2025.
  • Its Accumulated Depreciation & Amortization was $72.3 million in Q3 2025, compared to $48.9 million in Q2 2025 and $25.4 million in Q1 2025.